Source 1review2025MED
Toolkit/lipid nanoparticles
lipid nanoparticles
Also known as: lipid nanoparticles (LNPs), lipid nanoparticle vaccines, LNP, LNPs, mRNA-LNP, mRNA-LNP delivery systems, mRNA-LNPs, nanocarriers
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
This review examines recent advancements in nanoparticle( s) (NPs) delivery systems, with a focus on ... lipid nanoparticles (LNPs)... We discussed various NP platforms and their applications, such as ... dry powder formulations of mRNA-loaded LNPs for pulmonary delivery, and LNP-mediated siRNA delivery for respiratory infections.
Usefulness & Problems
Why this is useful
Lipid nanoparticles are described as a delivery system whose core-shell architecture protects nucleic acids, enhances cellular uptake, and enables efficient cytosolic delivery. In this review they are positioned as pivotal for cancer vaccination, especially mRNA-based approaches.; nucleic acid vaccine delivery; mRNA cancer vaccine delivery; cytosolic delivery of nucleic acids; Lipid nanoparticles are presented as carriers that encapsulate CRISPR components for in vivo delivery. The abstract links them to improved stability, circulation time, and targeting precision.; encapsulating CRISPR components; in vivo CRISPR delivery; Lipid nanoparticles are described as delivery systems for therapeutic mRNA vaccines. They protect mRNA from degradation and help move it into the cell cytoplasm.; mRNA delivery; protecting mRNA from degradation; facilitating cytoplasmic transport; Lipid nanoparticles are presented as the main nanocarrier platform enabling retinal mRNA delivery by intraocular administration. The abstract attributes improved mRNA stability, transfection efficiency, and preferential delivery to retinal neurons, Müller glia, and pigment epithelium to these carriers.; intraocular mRNA delivery; preferential delivery to retinal neurons, Müller glia, and pigment epithelium; improving mRNA stability; improving transfection efficiency; LNPs are presented as non-viral delivery systems for mRNA and occasionally for smaller nucleic acids such as siRNA. The article frames them as the central delivery platform for mRNA therapeutics and vaccines.; non-viral delivery of mRNA; delivery of smaller nucleic acids such as siRNA; LNPs are delivery vehicles that protect mRNA and transport it to target sites to support stable and efficient transfection. The abstract frames them as a core platform for mRNA therapeutics.; protecting and transporting mRNA to target sites; Lipid nanoparticles are presented as a leading platform for delivering mRNA melanoma vaccines. In the review abstract, personalized LNP-formulated mRNA vaccines are linked to stronger neoantigen-specific T-cell responses and improved recurrence-free survival.; delivery of mRNA melanoma vaccine constructs; personalized neoantigen vaccine formulation; Lipid nanoparticles are presented as a non-viral transfection system used to deliver nucleic acid therapeutics. The abstract specifically associates them with mRNA, siRNA, and antisense oligonucleotide delivery.; non-viral transfection; delivery of mRNA, siRNA, and antisense oligonucleotides; Lipid nanoparticles are described as gene-delivery platforms relevant to modulating the hepatic tumor niche in liver metastases.; gene delivery in the liver metastasis immunotherapy context; LNPs are presented as a nanovesicle platform for targeted hepatic delivery of drugs and genes. The abstract specifically highlights their efficiency in nucleic acid encapsulation and delivery.; hepatic drug delivery; hepatic gene delivery; nucleic acid encapsulation and delivery; Lipid nanoparticles are described as nanoparticle technologies that serve as delivery systems or adjuvant platforms across nucleic acid vaccine approaches. The abstract specifically cites them as an example of the delivery challenge for mRNA vaccines.; delivery of nucleic acid vaccine platforms; serving as delivery systems or adjuvant platforms; Lipid nanoparticles are described as an advanced nanotechnology formulation used in COVID-19 vaccines and therapeutic delivery. In this review they function as a controlled-delivery platform rather than as the therapeutic itself.; vaccine delivery; controlled delivery of therapeutics; COVID-19 treatment platform development; Lipid nanoparticles are identified as a widely studied nanocarrier class for siRNA delivery in rheumatoid arthritis.; nanocarrier-based siRNA delivery in rheumatoid arthritis; Lipid nanoparticles are described as a delivery innovation used in mRNA vaccine platforms. In this review, they are positioned as a major vehicle for translating mRNA design into vaccination applications.; mRNA vaccine delivery; LNPs are presented as delivery systems that help mRNA reach target cells and support expression of functional proteins. In this review, they are the central platform for targeted mRNA delivery in cancer therapy.; targeted mRNA delivery in cancer therapy; clinical translation of mRNA therapies; Lipid nanoparticles are described as a non-viral delivery system for retinal gene therapy. The review highlights them as part of recent delivery innovations improving efficiency and specificity.; non-viral retinal gene delivery; supporting RNA-based and other ocular gene therapy strategies; Lipid nanoparticles are presented as a non-viral delivery system for CRISPR-based therapeutic strategies in β-thalassemia.; non-viral delivery strategies for CRISPR-based β-thalassemia therapies; Lipid nanoparticles are presented as a central RNA delivery platform in the review. The abstract links them to pulmonary mRNA delivery, siRNA delivery for respiratory infections, intracellular delivery, and RNA release.; siRNA delivery; pulmonary delivery; respiratory infection applications; Lipid nanoparticles are treated as a named nanoparticle platform within the review's precision-delivery framework. They serve as a delivery harness rather than a target or disease concept.; nanoparticle-based drug delivery; precision delivery platform design; Lipid nanoparticles are described as a delivery system for mRNA vaccine cargo. The supplied summary links them to both non-replicating and self-amplifying RNA vaccine formats.; delivery of mRNA vaccine cargo; formulation of non-replicating mRNA vaccines; formulation of self-amplifying RNA vaccines
Source:
Lipid nanoparticles are described as a delivery system whose core-shell architecture protects nucleic acids, enhances cellular uptake, and enables efficient cytosolic delivery. In this review they are positioned as pivotal for cancer vaccination, especially mRNA-based approaches.
Source:
nucleic acid vaccine delivery
Source:
mRNA cancer vaccine delivery
Source:
cytosolic delivery of nucleic acids
Source:
Lipid nanoparticles are presented as carriers that encapsulate CRISPR components for in vivo delivery. The abstract links them to improved stability, circulation time, and targeting precision.
Source:
encapsulating CRISPR components
Source:
in vivo CRISPR delivery
Source:
Lipid nanoparticles are described as delivery systems for therapeutic mRNA vaccines. They protect mRNA from degradation and help move it into the cell cytoplasm.
Source:
mRNA delivery
Source:
protecting mRNA from degradation
Source:
facilitating cytoplasmic transport
Source:
Lipid nanoparticles are presented as the main nanocarrier platform enabling retinal mRNA delivery by intraocular administration. The abstract attributes improved mRNA stability, transfection efficiency, and preferential delivery to retinal neurons, Müller glia, and pigment epithelium to these carriers.
Source:
intraocular mRNA delivery
Source:
preferential delivery to retinal neurons, Müller glia, and pigment epithelium
Source:
improving mRNA stability
Source:
improving transfection efficiency
Source:
LNPs are presented as non-viral delivery systems for mRNA and occasionally for smaller nucleic acids such as siRNA. The article frames them as the central delivery platform for mRNA therapeutics and vaccines.
Source:
non-viral delivery of mRNA
Source:
delivery of smaller nucleic acids such as siRNA
Source:
LNPs are delivery vehicles that protect mRNA and transport it to target sites to support stable and efficient transfection. The abstract frames them as a core platform for mRNA therapeutics.
Source:
mRNA delivery
Source:
protecting and transporting mRNA to target sites
Source:
Lipid nanoparticles are presented as a leading platform for delivering mRNA melanoma vaccines. In the review abstract, personalized LNP-formulated mRNA vaccines are linked to stronger neoantigen-specific T-cell responses and improved recurrence-free survival.
Source:
delivery of mRNA melanoma vaccine constructs
Source:
personalized neoantigen vaccine formulation
Source:
Lipid nanoparticles are presented as a non-viral transfection system used to deliver nucleic acid therapeutics. The abstract specifically associates them with mRNA, siRNA, and antisense oligonucleotide delivery.
Source:
non-viral transfection
Source:
delivery of mRNA, siRNA, and antisense oligonucleotides
Source:
Lipid nanoparticles are described as gene-delivery platforms relevant to modulating the hepatic tumor niche in liver metastases.
Source:
gene delivery in the liver metastasis immunotherapy context
Source:
LNPs are presented as a nanovesicle platform for targeted hepatic delivery of drugs and genes. The abstract specifically highlights their efficiency in nucleic acid encapsulation and delivery.
Source:
hepatic drug delivery
Source:
hepatic gene delivery
Source:
nucleic acid encapsulation and delivery
Source:
Lipid nanoparticles are described as nanoparticle technologies that serve as delivery systems or adjuvant platforms across nucleic acid vaccine approaches. The abstract specifically cites them as an example of the delivery challenge for mRNA vaccines.
Source:
delivery of nucleic acid vaccine platforms
Source:
serving as delivery systems or adjuvant platforms
Source:
Lipid nanoparticles are described as an advanced nanotechnology formulation used in COVID-19 vaccines and therapeutic delivery. In this review they function as a controlled-delivery platform rather than as the therapeutic itself.
Source:
vaccine delivery
Source:
controlled delivery of therapeutics
Source:
COVID-19 treatment platform development
Source:
Lipid nanoparticles are identified as a widely studied nanocarrier class for siRNA delivery in rheumatoid arthritis.
Source:
nanocarrier-based siRNA delivery in rheumatoid arthritis
Source:
Lipid nanoparticles are described as a delivery innovation used in mRNA vaccine platforms. In this review, they are positioned as a major vehicle for translating mRNA design into vaccination applications.
Source:
mRNA vaccine delivery
Source:
LNPs are presented as delivery systems that help mRNA reach target cells and support expression of functional proteins. In this review, they are the central platform for targeted mRNA delivery in cancer therapy.
Source:
mRNA delivery
Source:
targeted mRNA delivery in cancer therapy
Source:
clinical translation of mRNA therapies
Source:
Lipid nanoparticles are described as a non-viral delivery system for retinal gene therapy. The review highlights them as part of recent delivery innovations improving efficiency and specificity.
Source:
non-viral retinal gene delivery
Source:
supporting RNA-based and other ocular gene therapy strategies
Source:
Lipid nanoparticles are presented as a non-viral delivery system for CRISPR-based therapeutic strategies in β-thalassemia.
Source:
non-viral delivery strategies for CRISPR-based β-thalassemia therapies
Source:
Lipid nanoparticles are presented as a central RNA delivery platform in the review. The abstract links them to pulmonary mRNA delivery, siRNA delivery for respiratory infections, intracellular delivery, and RNA release.
Source:
mRNA delivery
Source:
siRNA delivery
Source:
pulmonary delivery
Source:
respiratory infection applications
Source:
Lipid nanoparticles are treated as a named nanoparticle platform within the review's precision-delivery framework. They serve as a delivery harness rather than a target or disease concept.
Source:
nanoparticle-based drug delivery
Source:
precision delivery platform design
Source:
Lipid nanoparticles are described as a delivery system for mRNA vaccine cargo. The supplied summary links them to both non-replicating and self-amplifying RNA vaccine formats.
Source:
delivery of mRNA vaccine cargo
Source:
formulation of non-replicating mRNA vaccines
Source:
formulation of self-amplifying RNA vaccines
Problem solved
The platform addresses the need to deliver fragile nucleic acid vaccines into cells while preserving cargo and promoting intracellular delivery. This is presented as a key enabler for tumor-antigen and neoantigen vaccination.; protecting nucleic acid cargo; enhancing cellular uptake; enabling efficient cytosolic delivery; They help solve the delivery and stability bottleneck for CRISPR use in vivo.; improving stability of CRISPR cargo; improving circulation time; improving tumor-targeting precision; They address two central bottlenecks of mRNA therapeutics: instability and inefficient delivery to target cells.; improving stability of therapeutic mRNA; enabling delivery of mRNA to target cells; They solve a key delivery problem for retinal mRNA therapy by helping stabilize mRNA and improve transfection in ocular tissues.; enables non-viral retinal delivery of mRNA; improves stability and transfection efficiency of mRNA cargo; LNPs solve the need for a non-viral delivery system for mRNA-based therapeutics and vaccines. They also support delivery of some smaller nucleic acids.; provides a non-viral delivery system for RNA therapeutics and vaccines; They solve the problem of protecting fragile mRNA and moving it to target sites for delivery. This supports therapeutic use of mRNA.; improving mRNA stability during delivery; enabling efficient transfection; The platform addresses delivery of therapeutic mRNA vaccines for melanoma, especially personalized neoantigen vaccination. It is positioned as a way to augment antitumor immunity and support checkpoint inhibition.; provides a delivery platform for mRNA melanoma vaccines; They address the need for safer and more flexible delivery than viral vectors in next-generation therapies.; providing a safer, more flexible alternative to viral vectors; They address the need to deliver genetic payloads for next-generation immunotherapy strategies in liver metastases.; providing a gene-delivery platform to modulate the hepatic tumor niche; They are positioned as a way to improve therapeutic precision and reduce off-target effects in liver disease treatment.; improving therapeutic precision in liver disease delivery; reducing off-target effects relative to conventional treatments; They address the need to deliver nucleic acid vaccines in bacterial vaccine strategies. The abstract frames delivery as a central translational requirement.; supports delivery of mRNA and related vaccine platforms; They address the need to deliver therapeutics or vaccine cargo in a controlled nanoparticle format for COVID-19 applications.; enables nanoparticle-based delivery of vaccine or therapeutic payloads; They are included among systems intended to improve siRNA stability, uptake, and targeting to inflamed joints.; supports siRNA stability and delivery to inflamed joints; They address the need to deliver mRNA as part of vaccine platform design.; providing a delivery platform for mRNA vaccines; The platform addresses the need for effective delivery systems so therapeutic mRNA can efficiently enter target cells and function. This is framed as necessary for therapeutic efficacy.; enabling mRNA to enter target cells and express functional proteins; It offers a non-viral route for getting genetic material to the retina with improved delivery performance. This is relevant where conventional therapies do not address molecular causes.; improving efficiency and specificity of gene delivery to the retina; providing a non-viral delivery option; They address some safety concerns associated with viral vectors by offering lower toxicity and modularity.; providing a lower-toxicity and modular alternative to viral delivery; LNPs are used to improve delivery of RNA therapeutics to target cells and to support intracellular delivery and release of the RNA payload.; delivery of RNA cargos to target tissues; supporting intracellular delivery and RNA release; They provide a lipid-based route for packaging and delivering therapeutics in nanoparticle form. The review context suggests they are engineered to navigate delivery barriers.; providing a lipid-based nanoparticle platform for therapeutic cargo delivery; They address the delivery problem for mRNA vaccines by serving as a core carrier system.; enables delivery of mRNA vaccine material
Source:
The platform addresses the need to deliver fragile nucleic acid vaccines into cells while preserving cargo and promoting intracellular delivery. This is presented as a key enabler for tumor-antigen and neoantigen vaccination.
Source:
protecting nucleic acid cargo
Source:
enhancing cellular uptake
Source:
enabling efficient cytosolic delivery
Source:
They help solve the delivery and stability bottleneck for CRISPR use in vivo.
Source:
improving stability of CRISPR cargo
Source:
improving circulation time
Source:
improving tumor-targeting precision
Source:
They address two central bottlenecks of mRNA therapeutics: instability and inefficient delivery to target cells.
Source:
improving stability of therapeutic mRNA
Source:
enabling delivery of mRNA to target cells
Source:
They solve a key delivery problem for retinal mRNA therapy by helping stabilize mRNA and improve transfection in ocular tissues.
Source:
enables non-viral retinal delivery of mRNA
Source:
improves stability and transfection efficiency of mRNA cargo
Source:
LNPs solve the need for a non-viral delivery system for mRNA-based therapeutics and vaccines. They also support delivery of some smaller nucleic acids.
Source:
provides a non-viral delivery system for RNA therapeutics and vaccines
Source:
They solve the problem of protecting fragile mRNA and moving it to target sites for delivery. This supports therapeutic use of mRNA.
Source:
improving mRNA stability during delivery
Source:
enabling efficient transfection
Source:
The platform addresses delivery of therapeutic mRNA vaccines for melanoma, especially personalized neoantigen vaccination. It is positioned as a way to augment antitumor immunity and support checkpoint inhibition.
Source:
provides a delivery platform for mRNA melanoma vaccines
Source:
They address the need for safer and more flexible delivery than viral vectors in next-generation therapies.
Source:
providing a safer, more flexible alternative to viral vectors
Source:
They address the need to deliver genetic payloads for next-generation immunotherapy strategies in liver metastases.
Source:
providing a gene-delivery platform to modulate the hepatic tumor niche
Source:
They are positioned as a way to improve therapeutic precision and reduce off-target effects in liver disease treatment.
Source:
improving therapeutic precision in liver disease delivery
Source:
reducing off-target effects relative to conventional treatments
Source:
They address the need to deliver nucleic acid vaccines in bacterial vaccine strategies. The abstract frames delivery as a central translational requirement.
Source:
supports delivery of mRNA and related vaccine platforms
Source:
They address the need to deliver therapeutics or vaccine cargo in a controlled nanoparticle format for COVID-19 applications.
Source:
enables nanoparticle-based delivery of vaccine or therapeutic payloads
Source:
They are included among systems intended to improve siRNA stability, uptake, and targeting to inflamed joints.
Source:
supports siRNA stability and delivery to inflamed joints
Source:
They address the need to deliver mRNA as part of vaccine platform design.
Source:
providing a delivery platform for mRNA vaccines
Source:
The platform addresses the need for effective delivery systems so therapeutic mRNA can efficiently enter target cells and function. This is framed as necessary for therapeutic efficacy.
Source:
enabling mRNA to enter target cells and express functional proteins
Source:
It offers a non-viral route for getting genetic material to the retina with improved delivery performance. This is relevant where conventional therapies do not address molecular causes.
Source:
improving efficiency and specificity of gene delivery to the retina
Source:
providing a non-viral delivery option
Source:
They address some safety concerns associated with viral vectors by offering lower toxicity and modularity.
Source:
providing a lower-toxicity and modular alternative to viral delivery
Source:
LNPs are used to improve delivery of RNA therapeutics to target cells and to support intracellular delivery and release of the RNA payload.
Source:
delivery of RNA cargos to target tissues
Source:
supporting intracellular delivery and RNA release
Source:
They provide a lipid-based route for packaging and delivering therapeutics in nanoparticle form. The review context suggests they are engineered to navigate delivery barriers.
Source:
providing a lipid-based nanoparticle platform for therapeutic cargo delivery
Source:
They address the delivery problem for mRNA vaccines by serving as a core carrier system.
Source:
enables delivery of mRNA vaccine material
Problem links
Under-Provisioning of Antibiotics, Vaccines and Other Interventions for Major Global Health Challenges
Gap mapView gapThe gap explicitly calls for novel vaccine technologies and improved therapeutic delivery, and this item is a concrete non-viral platform for mRNA, siRNA, and CRISPR cargo. The summary also mentions respiratory infection use cases and dry-powder pulmonary formulations, which plausibly align with scalable interventions for infectious disease.
Lack of Infrastructure Technologies and Strategies Optimized for Low-Resource Settings
Gap mapView gapThe gap includes decentralized, low-resource vaccine production and distribution challenges, and this item is a non-viral nucleic-acid delivery platform with explicit mRNA therapeutic relevance. Its mention of dry-powder pulmonary formulations also makes it plausibly relevant to infrastructure-constrained deployment strategies.
LNPs are a directly actionable in vivo delivery strategy and could be useful when testing how nucleic-acid therapeutics distribute and act in the body, which touches the gap's delivery and exposure-prediction bottleneck. They help generate relevant physiology-facing test systems, though they are not themselves a predictive ADME/Tox model.
delivery of RNA cargos to target tissues
LiteratureLNPs are used to improve delivery of RNA therapeutics to target cells and to support intracellular delivery and release of the RNA payload.
Source:
LNPs are used to improve delivery of RNA therapeutics to target cells and to support intracellular delivery and release of the RNA payload.
enables delivery of mRNA vaccine material
LiteratureThey address the delivery problem for mRNA vaccines by serving as a core carrier system.
Source:
They address the delivery problem for mRNA vaccines by serving as a core carrier system.
enables nanoparticle-based delivery of vaccine or therapeutic payloads
LiteratureThey address the need to deliver therapeutics or vaccine cargo in a controlled nanoparticle format for COVID-19 applications.
Source:
They address the need to deliver therapeutics or vaccine cargo in a controlled nanoparticle format for COVID-19 applications.
enables non-viral retinal delivery of mRNA
LiteratureThey solve a key delivery problem for retinal mRNA therapy by helping stabilize mRNA and improve transfection in ocular tissues.
Source:
They solve a key delivery problem for retinal mRNA therapy by helping stabilize mRNA and improve transfection in ocular tissues.
enabling delivery of mRNA to target cells
LiteratureThey address two central bottlenecks of mRNA therapeutics: instability and inefficient delivery to target cells.
Source:
They address two central bottlenecks of mRNA therapeutics: instability and inefficient delivery to target cells.
enabling efficient cytosolic delivery
LiteratureThe platform addresses the need to deliver fragile nucleic acid vaccines into cells while preserving cargo and promoting intracellular delivery. This is presented as a key enabler for tumor-antigen and neoantigen vaccination.
Source:
The platform addresses the need to deliver fragile nucleic acid vaccines into cells while preserving cargo and promoting intracellular delivery. This is presented as a key enabler for tumor-antigen and neoantigen vaccination.
enabling efficient transfection
LiteratureThey solve the problem of protecting fragile mRNA and moving it to target sites for delivery. This supports therapeutic use of mRNA.
Source:
They solve the problem of protecting fragile mRNA and moving it to target sites for delivery. This supports therapeutic use of mRNA.
enabling mRNA to enter target cells and express functional proteins
LiteratureThe platform addresses the need for effective delivery systems so therapeutic mRNA can efficiently enter target cells and function. This is framed as necessary for therapeutic efficacy.
Source:
The platform addresses the need for effective delivery systems so therapeutic mRNA can efficiently enter target cells and function. This is framed as necessary for therapeutic efficacy.
enhancing cellular uptake
LiteratureThe platform addresses the need to deliver fragile nucleic acid vaccines into cells while preserving cargo and promoting intracellular delivery. This is presented as a key enabler for tumor-antigen and neoantigen vaccination.
Source:
The platform addresses the need to deliver fragile nucleic acid vaccines into cells while preserving cargo and promoting intracellular delivery. This is presented as a key enabler for tumor-antigen and neoantigen vaccination.
improves stability and transfection efficiency of mRNA cargo
LiteratureThey solve a key delivery problem for retinal mRNA therapy by helping stabilize mRNA and improve transfection in ocular tissues.
Source:
They solve a key delivery problem for retinal mRNA therapy by helping stabilize mRNA and improve transfection in ocular tissues.
improving circulation time
LiteratureThey help solve the delivery and stability bottleneck for CRISPR use in vivo.
Source:
They help solve the delivery and stability bottleneck for CRISPR use in vivo.
improving efficiency and specificity of gene delivery to the retina
LiteratureIt offers a non-viral route for getting genetic material to the retina with improved delivery performance. This is relevant where conventional therapies do not address molecular causes.
Source:
It offers a non-viral route for getting genetic material to the retina with improved delivery performance. This is relevant where conventional therapies do not address molecular causes.
improving mRNA stability during delivery
LiteratureThey solve the problem of protecting fragile mRNA and moving it to target sites for delivery. This supports therapeutic use of mRNA.
Source:
They solve the problem of protecting fragile mRNA and moving it to target sites for delivery. This supports therapeutic use of mRNA.
improving stability of CRISPR cargo
LiteratureThey help solve the delivery and stability bottleneck for CRISPR use in vivo.
Source:
They help solve the delivery and stability bottleneck for CRISPR use in vivo.
improving stability of therapeutic mRNA
LiteratureThey address two central bottlenecks of mRNA therapeutics: instability and inefficient delivery to target cells.
Source:
They address two central bottlenecks of mRNA therapeutics: instability and inefficient delivery to target cells.
improving therapeutic precision in liver disease delivery
LiteratureThey are positioned as a way to improve therapeutic precision and reduce off-target effects in liver disease treatment.
Source:
They are positioned as a way to improve therapeutic precision and reduce off-target effects in liver disease treatment.
improving tumor-targeting precision
LiteratureThey help solve the delivery and stability bottleneck for CRISPR use in vivo.
Source:
They help solve the delivery and stability bottleneck for CRISPR use in vivo.
protecting nucleic acid cargo
LiteratureThe platform addresses the need to deliver fragile nucleic acid vaccines into cells while preserving cargo and promoting intracellular delivery. This is presented as a key enabler for tumor-antigen and neoantigen vaccination.
Source:
The platform addresses the need to deliver fragile nucleic acid vaccines into cells while preserving cargo and promoting intracellular delivery. This is presented as a key enabler for tumor-antigen and neoantigen vaccination.
provides a delivery platform for mRNA melanoma vaccines
LiteratureThe platform addresses delivery of therapeutic mRNA vaccines for melanoma, especially personalized neoantigen vaccination. It is positioned as a way to augment antitumor immunity and support checkpoint inhibition.
Source:
The platform addresses delivery of therapeutic mRNA vaccines for melanoma, especially personalized neoantigen vaccination. It is positioned as a way to augment antitumor immunity and support checkpoint inhibition.
provides a non-viral delivery system for RNA therapeutics and vaccines
LiteratureLNPs solve the need for a non-viral delivery system for mRNA-based therapeutics and vaccines. They also support delivery of some smaller nucleic acids.
Source:
LNPs solve the need for a non-viral delivery system for mRNA-based therapeutics and vaccines. They also support delivery of some smaller nucleic acids.
providing a delivery platform for mRNA vaccines
LiteratureThey address the need to deliver mRNA as part of vaccine platform design.
Source:
They address the need to deliver mRNA as part of vaccine platform design.
providing a gene-delivery platform to modulate the hepatic tumor niche
LiteratureThey address the need to deliver genetic payloads for next-generation immunotherapy strategies in liver metastases.
Source:
They address the need to deliver genetic payloads for next-generation immunotherapy strategies in liver metastases.
providing a lipid-based nanoparticle platform for therapeutic cargo delivery
LiteratureThey provide a lipid-based route for packaging and delivering therapeutics in nanoparticle form. The review context suggests they are engineered to navigate delivery barriers.
Source:
They provide a lipid-based route for packaging and delivering therapeutics in nanoparticle form. The review context suggests they are engineered to navigate delivery barriers.
providing a lower-toxicity and modular alternative to viral delivery
LiteratureThey address some safety concerns associated with viral vectors by offering lower toxicity and modularity.
Source:
They address some safety concerns associated with viral vectors by offering lower toxicity and modularity.
providing a non-viral delivery option
LiteratureIt offers a non-viral route for getting genetic material to the retina with improved delivery performance. This is relevant where conventional therapies do not address molecular causes.
Source:
It offers a non-viral route for getting genetic material to the retina with improved delivery performance. This is relevant where conventional therapies do not address molecular causes.
providing a safer, more flexible alternative to viral vectors
LiteratureThey address the need for safer and more flexible delivery than viral vectors in next-generation therapies.
Source:
They address the need for safer and more flexible delivery than viral vectors in next-generation therapies.
reducing off-target effects relative to conventional treatments
LiteratureThey are positioned as a way to improve therapeutic precision and reduce off-target effects in liver disease treatment.
Source:
They are positioned as a way to improve therapeutic precision and reduce off-target effects in liver disease treatment.
supporting intracellular delivery and RNA release
LiteratureLNPs are used to improve delivery of RNA therapeutics to target cells and to support intracellular delivery and release of the RNA payload.
Source:
LNPs are used to improve delivery of RNA therapeutics to target cells and to support intracellular delivery and release of the RNA payload.
supports delivery of mRNA and related vaccine platforms
LiteratureThey address the need to deliver nucleic acid vaccines in bacterial vaccine strategies. The abstract frames delivery as a central translational requirement.
Source:
They address the need to deliver nucleic acid vaccines in bacterial vaccine strategies. The abstract frames delivery as a central translational requirement.
supports siRNA stability and delivery to inflamed joints
LiteratureThey are included among systems intended to improve siRNA stability, uptake, and targeting to inflamed joints.
Source:
They are included among systems intended to improve siRNA stability, uptake, and targeting to inflamed joints.
Published Workflows
Objective: Identify and advance effective mRNA-based melanoma vaccine strategies by pairing delivery platform choice with personalized antigen design and immunologic optimization.
Why it works: The review abstract links platform engineering and personalization to immune activation, then notes that combination with checkpoint inhibitors and optimization of DC maturation can further strengthen responses.
broadening T-cell responsesenhancing checkpoint inhibitionoptimizing dendritic-cell maturationpersonalized neoantigen designLNP formulationdendritic-cell priming
Stages
- 1.Literature identification across major databases(in_silico_filter)
The review first defines the evidence base by searching MEDLINE, Embase, and Scopus before drawing conclusions about delivery platforms and vaccine strategies.
Selection: Clinical trials, preclinical studies, and review articles evaluating mRNA vaccine constructs and delivery strategies from 2015 to 2025
- 2.Platform-focused evidence comparison(functional_characterization)
The review centers on comparing the two leading delivery platforms to understand how each supports antitumor immunity in melanoma.
Selection: Comparison of two leading delivery platforms, LNPs and dendritic-cell vaccines, for immunogenicity and clinical activity
- 3.Combination and optimization assessment(secondary_characterization)
After identifying active platforms, the review highlights optimization levers that may improve response quality and translational performance.
Selection: Assessment of checkpoint inhibitor combinations, DC maturation optimization, next-generation LNP formulations, and DC priming strategies
- 4.Translation readiness and scalability consideration(decision_gate)
The review explicitly states that delivery, antigen selection, and manufacturing refinement are essential for full clinical realization.
Selection: Need for refinement of delivery vehicles, neoantigen selection, and scalable manufacturing processes
Objective: Develop LNP-based mRNA therapeutics and vaccines into stable and safe drug products suitable for human application.
Why it works: The abstract states that numerous factors influence product quality and that proper understanding and control of critical variables is essential. It also states that strategies to identify failure risks early and mitigate them are part of the roadmap.
non-viral delivery of mRNAcontrol of LNP compositioncontrol of process parameterscontrol of formulation compositionLNP designLNP manufacturing process developmentanalytical developmentformulation developmentearly failure-risk identificationrisk mitigation
Stages
- 1.LNP design(library_design)
The roadmap covers LNP design as an early development step because LNP composition is one of the factors influencing product quality.
Selection: quality target product profile and current scientific and technical knowledge
- 2.LNP manufacturing process development(library_build)
Manufacturing process development is included because process parameters influence product quality and scalable equipment is available, but development remains nontrivial.
Selection: control of process parameters affecting product quality
- 3.Analytical development(secondary_characterization)
Analytical development is part of the roadmap to understand and control critical variables and to identify failure risks early in development.
Selection: understanding and control of critical variables impacting product quality
- 4.Formulation development(functional_characterization)
Formulation development is included to achieve a stable and safe product suitable for human application.
Selection: formulation composition and related factors that impact product quality
Objective: To provide a comprehensive bibliometric assessment of the current status, hotspots, and future directions of nanoparticle applications in influenza research.
Why it works: The study combines searches across Web of Science Core Collection, Scopus, and PubMed to improve completeness, and uses Bibliometrix, CiteSpace, and VOSviewer to compensate for differences in their respective algorithms.
publication database searchbibliometric analysiskeyword analysis
Stages
- 1.Publication search across literature databases(broad_screen)
This stage exists to improve the completeness of the publication collection before downstream bibliometric analysis.
Selection: publications on nanoparticles and influenza from 2005 to 2025 collected from Web of Science Core Collection, Scopus, and PubMed
- 2.Multi-software bibliometric analysis(secondary_characterization)
This stage exists to characterize the collected literature using complementary bibliometric algorithms.
Selection: analysis of publication quantity, citation counts, and co-authorship using Bibliometrix, CiteSpace, and VOSviewer
- 3.Keyword hotspot analysis(secondary_characterization)
This stage exists to identify major thematic priorities and emerging directions in nanoparticle influenza research.
Selection: keyword analysis of the publication corpus
Steps
- 1.Search Web of Science Core Collection, Scopus, and PubMed for 2005-2025 publications
Assemble a comprehensive literature corpus on nanoparticles and influenza.
The publication corpus must be collected before bibliometric analyses can be performed.
- 2.Analyze the corpus with Bibliometrix, CiteSpace, and VOSviewerbibliometric analysis software
Characterize publication quantity, citation counts, and co-authorship patterns using complementary algorithms.
This follows corpus assembly because bibliometric software requires the collected publication dataset as input.
- 3.Perform keyword analysis to identify research hotspots
Infer central priorities and emerging directions in nanoparticle influenza research.
After the corpus is assembled and bibliometric characterization is performed, keyword analysis is used to interpret thematic hotspots.
Objective: Engineer and preliminarily evaluate a FAP-targeted CAR design for fibrosis-selective cytotoxicity against cardiac myofibroblasts.
Why it works: The workflow uses engineered Jurkat cells as a preliminary screening model to test whether the FAP-targeted 4-1BB CAR can be expressed and can mediate target recognition and cytotoxicity before moving to primary T cell models.
selective recognition of FAP-expressing cardiac myofibroblastsapoptosis induction in target myofibroblastscell engineering using lentiviral vectorscell engineering using lipid nanoparticlespreliminary screening in Jurkat cells
Stages
- 1.Generation of FAP-CAR-engineered Jurkat screening model(library_build)
This stage creates the engineered cell model needed for downstream evaluation of CAR expression and function.
Selection: Generate engineered Jurkat cells carrying the FAP-targeted CAR using lentiviral vectors or lipid nanoparticles.
- 2.Preliminary in vitro functional screening(broad_screen)
This stage tests whether the engineered CAR design is functional in vitro before further investigation in primary T cell models.
Selection: Evaluate CAR expression, target recognition, and in vitro cytotoxic activity in the engineered Jurkat model.
- 3.Target-cell apoptosis and cytokine assessment(confirmatory_validation)
This stage confirms target-specific functional activity and checks a safety-relevant cytokine signal in the in vitro system.
Selection: Confirm selective recognition and apoptosis induction in FAP-expressing cardiac myofibroblasts while checking for excessive IL-6 secretion.
Steps
- 1.Engineer Jurkat cells with the FAP-targeted 4-1BB CAR using two delivery approachesengineered construct
Create a preliminary screening model for evaluating the FAP-targeted CAR design.
The engineered Jurkat model must be generated before CAR expression and functional activity can be tested.
- 2.Evaluate CAR expression, target recognition, and in vitro cytotoxic activityengineered screening model
Determine whether the engineered CAR is expressed and functionally engages target cells in vitro.
Expression and basic functional screening are used as the preliminary evaluation of the construct before stronger claims about therapeutic relevance.
- 3.Assess apoptosis in FAP-expressing cardiac myofibroblasts and monitor IL-6 secretionengineered effector cells
Confirm fibrosis-selective cytotoxicity and check for a safety-relevant cytokine signal.
After establishing expression and cytotoxic activity, the study tests whether target-cell killing is accompanied by apoptosis induction without excessive IL-6 secretion.
Objective: Optimize mRNA vaccine lipid nanoparticle delivery strategies for safer and more targeted performance while reducing off-target immune activation using a fully in silico framework.
Why it works: The workflow combines mechanistic immune modeling with synthetic transcriptomic readouts to estimate immune activation risk, then uses a predictive model and genetic algorithm to search nanoparticle design space before experimental validation.
immune-response modelingtranscriptomic response profilingimmune activation risk estimationsynthetic transcriptomicsdifferential gene expression analysisRandom Forest regressiongenetic algorithm optimizationfully in silico screening
Stages
- 1.Synthetic transcriptomics generation(library_design)
This stage creates the synthetic transcriptomic inputs needed to profile compartment-specific responses in silico.
Selection: Generate biologically informed synthetic RNA-seq datasets that emulate post-vaccination gene expression profiles in immune-related tissues.
- 2.Differential expression and immune risk scoring(secondary_characterization)
This stage converts synthetic transcriptomic outputs into a risk signal that can guide optimization.
Selection: Identify compartment-specific transcriptional responses and construct a risk index based on predicted immune activation and upregulated immune markers.
- 3.Predictive modeling of formulation immune activation(functional_characterization)
This stage provides a predictive scoring function for candidate nanoparticle formulations.
Selection: Train a Random Forest regression model on simulated lipid nanoparticle formulations to predict immune activation values.
- 4.Genetic algorithm optimization of nanoparticle design(selection)
This stage searches the nanoparticle design space to prioritize candidate formulations before experimental validation.
Selection: Use the embedded Random Forest model within a genetic algorithm to identify optimal lipid nanoparticle design parameters including size, charge, polyethylene glycol content, and targeting.
Steps
- 1.Generate biologically informed synthetic RNA-seq datasets
Create in silico transcriptomic data that emulate post-vaccination gene expression in immune-related tissues.
Synthetic datasets are needed before differential expression analysis and risk scoring can be performed.
- 2.Perform differential gene expression analysis to identify compartment-specific transcriptional responses
Extract compartment-specific transcriptional response patterns from the synthetic RNA-seq data.
Differential expression analysis must precede risk index construction because the transcriptional response features are used to build the index.
- 3.Construct immune activation risk indexrisk scoring method
Summarize predicted immune activation and upregulated immune marker counts into a risk index for candidate evaluation.
The risk index is built from the transcriptional responses identified in the previous analysis step.
- 4.Train Random Forest regression model on simulated lipid nanoparticle formulationspredictive model
Learn to predict immune activation values from simulated lipid nanoparticle formulations.
A trained predictive model is required before optimization can search formulation space efficiently.
- 5.Embed predictive model into genetic algorithm to identify optimal nanoparticle design parametersoptimization engine with embedded predictor
Search for optimal lipid nanoparticle design parameters including size, charge, polyethylene glycol content, and targeting.
The optimization step depends on the trained predictive model to score candidate designs during search.
Objective: Use computational approaches to accelerate nanocarrier design and optimize nanodelivery system properties for improved therapeutic performance.
Why it works: The abstract states that MD provides mechanistic insight into nanoparticle-membrane interactions, while AI analyzes large chemical datasets to predict optimal structures. Together these in silico approaches are presented as enabling rapid refinement of nanoparticle composition before or alongside experimental validation.
nanoparticle interactions with biological membraneseffects of surface charge density on uptake and stabilityeffects of ligand functionalisation on uptake and stabilityeffects of nanoparticle size on uptake and stabilityMolecular Dynamics simulationsArtificial Intelligence-driven modelingin silico guided experimental validation
Stages
- 1.In silico modeling and prediction(in_silico_filter)
This stage exists to accelerate nanocarrier design and optimize properties before experimental validation by using MD for mechanistic insight and AI for structure prediction.
Selection: Mechanistic insight from MD and predictive analysis from AI are used to evaluate nanoparticle properties and candidate structures.
- 2.Experimental validation(confirmatory_validation)
The abstract explicitly states that in silico models guide experimental validation, indicating a downstream confirmation stage for computationally informed designs.
Selection: In silico-guided designs are experimentally validated.
Steps
- 1.Model nanoparticle interactions and predict favorable formulationscomputational methods used to analyze and prioritize nanocarrier designs
Use MD to understand membrane interactions and AI to predict optimal lipid nanoparticle structures.
The abstract presents computational approaches as tools that accelerate design and guide later experimental validation, so this analysis occurs before downstream validation.
- 2.Experimentally validate in silico-guided designs
Confirm whether computationally informed nanocarrier designs support improved therapeutic performance.
The abstract explicitly states that in silico models guide experimental validation, making validation a downstream step after computational prioritization.
Objective: Evaluate the promise and comparative potential of lipid nanoparticles, extracellular vesicles, and liposomes for hepatic drug or gene delivery in liver disease therapy.
Why it works: The review uses a systematic search and comparative analysis across preclinical and clinical studies to assess vesicle composition, targeting efficiency, payload capacity, therapeutic outcomes, and limitations across three nanovesicle platforms.
targeted hepatic deliveryreduction of off-target effectssystematic search of peer-reviewed studiescomparative analysis of preclinical and clinical research
Stages
- 1.systematic search of peer-reviewed studies(broad_screen)
This stage identifies the body of literature relevant to hepatic drug or gene delivery using the three nanovesicle platforms under review.
Selection: peer-reviewed studies in electronic databases focused on preclinical and clinical research investigating LNPs, EVs, and liposomes for hepatic drug or gene delivery
- 2.comparative analysis of included studies(secondary_characterization)
This stage compares the included nanovesicle platforms on delivery-relevant and translationally relevant properties.
Selection: analysis of vesicle composition, targeting efficiency, payload capacity, therapeutic outcomes, and reported limitations
Objective: Deploy nanotechnology against COVID-19 across the outbreak-control priorities of prevention, early detection, and treatment.
Why it works: The review organizes nanotechnology applications around the public-health sequence of prevention, early detection, and treatment, matching different nanomaterial functions to each objective.
viral inactivationsensitive detectioncontrolled delivery of therapeuticsnanomaterial engineeringbiosensor developmentpoint-of-care diagnostic engineeringnanocarrier formulation
Stages
- 1.Prevention applications(decision_gate)
The review places prevention first in line with WHO outbreak-control priorities.
Selection: Use nanotechnology to reduce exposure risk through enhanced PPE, antiviral surfaces, and disinfectants.
- 2.Early detection and diagnosis applications(functional_characterization)
The review identifies early detection as a core outbreak-control strategy and maps diagnostic nanotechnologies to that need.
Selection: Use nanoparticle and nanosensor systems for rapid point-of-care and sensitive detection.
- 3.Treatment and therapeutic delivery applications(functional_characterization)
The review places treatment after prevention and diagnosis as the third major strategy.
Selection: Use nanoparticle vaccine and delivery platforms to support treatment efforts and controlled therapeutic delivery.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A delivery strategy grouped with the mechanism branch because it determines how a system is instantiated and deployed in context.
Mechanisms
circulation-time extensioncytosolic deliveryDegradationenhanced cellular uptakenucleic acid encapsulation and protectionstability enhancementTranslation ControlTarget processes
degradationeditingmanufacturingrecombinationselectiontranslationInput: Chemical
Implementation Constraints
cofactor dependency: requires exogenous cofactorencoding mode: externally suppliedimplementation constraint: context specific validationimplementation constraint: payload burdenoperating role: delivery
Use requires nucleic acid cargo such as siRNA or mRNA and a formulated LNP system. The abstract also indicates practical requirements around manufacturing quality and cold-chain handling.; requires scalable manufacturing with batch consistency; may require cold-chain logistics; safety concerns include reactogenicity and anti-PEG antibodies; Use requires CRISPR cargo to be formulated inside lipid nanoparticles. The NTLA-2001 example indicates human in vivo deployment is possible.; requires formulation of CRISPR components into lipid nanoparticles; They require formulated mRNA cargo and a delivery context where cytoplasmic entry is needed. The abstract does not specify composition or manufacturing details.; must be paired with mRNA cargo; must support intracellular delivery to the cytoplasm; Their use requires formulated mRNA cargo and intraocular administration. The review also emphasizes carrier selection, targeting, penetration, and controlled-release considerations.; requires intraocular administration; carrier selection is important for rational trial design; The abstract indicates that established manufacturing processes, scalable production equipment, analytical development, and formulation development are required. Control of LNP composition, process parameters, and formulation composition is also required.; requires understanding and control of critical variables affecting product quality; requires design, manufacturing, analytical development, and formulation development to achieve a stable and safe product suitable for human application; Use requires mRNA cargo and a formulated lipid nanoparticle system. The abstract also indicates that formulation design and screening are important practical requirements.; requires formulation optimization; performance depends on target-site delivery properties; Use of this platform requires an mRNA vaccine construct and a formulation process for LNP delivery. The review also highlights scalable manufacturing as an important prerequisite for broader clinical realization.; requires mRNA vaccine formulation; clinical impact is discussed in the context of personalized neoantigen approaches; manufacturing scalability remains an important consideration; Their use is discussed in the context of mRNA and other nucleic acid vaccine platforms, implying formulation with those vaccine cargos. No composition details are provided in the abstract.; requires integration with nucleic acid vaccine platforms; Use requires an LNP formulation carrying a vaccine or therapeutic payload. The abstract does not provide composition or manufacturing details.; requires nanoparticle formulation as a delivery system; used in vaccine or therapeutic delivery contexts; Their use requires nanoparticle formulation with siRNA cargo and downstream evaluation of pharmacokinetics, immunogenicity, and quality attributes.; must be formulated for siRNA delivery and meet translational manufacturing and safety requirements; delivery efficiency remains a critical challenge; Use requires mRNA cargo and an LNP formulation whose composition can be optimized. The abstract also indicates that synthesis methods and targeted delivery strategies are relevant implementation components.; requires optimization of LNP composition; targeted delivery remains an active design challenge; This approach requires nanoparticle formulation and ocular delivery compatible with the retinal environment. The abstract also indicates that retinal anatomical barriers still matter for implementation.; must overcome blood-retinal barrier constraints; retinal cell-type transduction can remain limited; efficient targeting remains a challenge; Use requires LNP formulation with the intended RNA cargo, and in some cases route-specific formats such as dry powder formulations for pulmonary delivery. The abstract also notes optimization strategies such as lipid tail modification.; requires nanoparticle formulation matched to RNA cargo and route of administration; Use requires an LNP formulation workflow and a therapeutic cargo to deliver, although the supplied payload does not specify exact components. The evidence only supports their inclusion as a major platform class.; requires lipid nanoparticle formulation and deployment as a delivery vehicle; Use requires formulated mRNA cargo and nanoparticle preparation. The payload also indicates related formulation components such as PEG-lipids may be involved in some particle formats.; requires particle formulation with mRNA cargo
The abstract states that LNPs do not by themselves solve manufacturing cost, batch consistency, physicochemical instability, reactogenicity, anti-PEG immunity, or poor lymphoid targeting. Tumor immunosuppression and heterogeneous antigen expression also remain limiting factors.; manufacturing cost and batch consistency challenge scale-up; physicochemical instability necessitates cold-chain logistics; reactogenicity and anti-PEG antibodies increase safety and dosing concerns; suboptimal lymphoid targeting can limit vaccine efficacy; The abstract says solid-tumor delivery, off-target effects, and formulation inconsistency remain unresolved.; limited delivery to solid tumors; potential off-target effects; inconsistent nanoparticle formulations; The abstract does not claim that LNPs fully solve all scientific and technological barriers to therapeutic mRNA vaccine implementation.; the abstract still frames effective delivery as a broader unresolved challenge; The abstract indicates that despite encouraging preclinical outcomes, these formulations have not yet advanced into retinal clinical trials. Thus they do not yet solve the clinical translation bottleneck.; no retinal clinical trial candidates have progressed according to the abstract; The abstract explicitly states that LNP drug product development is not straightforward and that many variables can compromise product quality. It does not claim that LNPs by themselves guarantee stability, safety, or manufacturability without further development work.; drug product development is not straightforward; product quality is influenced by numerous factors including composition and process parameters; The abstract states that current mRNA-LNP systems still face limited targeting specificity and formulation complexity. Development is also slowed by time-consuming screening.; limited targeting specificity; formulation complexity; time-consuming high-throughput screening during development; The abstract does not show that LNP delivery alone solves all clinical bottlenecks. It explicitly notes that delivery vehicles, neoantigen selection, and manufacturing still need refinement.; requires continued refinement of delivery vehicles; full clinical potential depends on scalable manufacturing processes; The abstract does not indicate that lipid nanoparticles solve antigen discovery or broader translational hurdles. Delivery itself is still presented as a challenge.; delivery remains a challenge; The abstract does not show that LNPs alone provide prevention, diagnosis, and treatment across all use cases, and it does not resolve regulatory or translational barriers.; the abstract notes regulatory and translational challenges for nanotechnologies but does not specify LNP-specific limitations; The abstract does not claim that lipid nanoparticles fully overcome translational barriers such as protein corona effects or long-term biosafety.; carrier platforms still face translational barriers including systemic stability, protein corona formation, endosomal escape efficiency, manufacturing consistency, and biosafety; The abstract indicates that delivery efficiency and large-scale translation challenges still persist despite progress.; the abstract notes persistent challenges in delivery efficiency; The abstract does not support a claim that lipid nanoparticles fully overcome all retinal barriers or cell-type transduction problems. It also does not specify disease-by-disease performance.; abstract does not specify which retinal cell types or cargos are best served; anatomical barriers and limited transduction efficiency remain field-wide challenges; The abstract states that these systems still face targeting limitations.; targeting limitations; The abstract explicitly states that targeting efficiency, endosomal escape, stability, immune interactions, and scalability are still unresolved challenges.; targeting efficiency remains a challenge; endosomal escape remains a challenge; stability remains a challenge; immune system interactions remain a challenge; scalability remains a challenge; The provided evidence does not establish that LNPs alone solve all biodistribution, immune, or intracellular delivery bottlenecks. It also does not provide a protocol-level recipe.; the provided payload does not specify cargo compatibility, formulation details, or comparative performance
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Observations
successHuman Clinicaltherapeutic use
Inferred from claim c2 during normalization. The NTLA-2001 trial demonstrated the first successful use of lipid nanoparticles for in vivo CRISPR delivery in humans. Derived from claim c2.
Source:
failedHuman Clinicalfailed attempt
Inferred from claim c7 during normalization. Despite encouraging preclinical outcomes of lipid nanoparticle-mRNA formulations, no candidates have progressed into retinal clinical trials. Derived from claim c7.
Source:
Supporting Sources
Source 2review2026MED
Source 3primary paper2025MED
Source 4primary paper2026MED
Source 5review2025MED
Source 6primary paper2026MED
Source 7review2020Nature Reviews Drug Discovery
Source 8primary paper2025MED
Source 9primary paper2025MED
Source 10primary paper2026MED
Source 11review2025MED
Source 12primary paper2025MED
Source 13primary paper2026MED
Source 14primary paper2025MED
Source 15primary paper2025MED
Source 16primary paper2025MED
Source 17review2026MED
Source 18primary paper2026MED
Source 19primary paper2025MED
Source 20review2018Nature Reviews Drug Discovery
Ranked Claims
Combining AI with LNP technology can enable more personalized and precise delivery systems, streamline development, and reduce cost.
The combination of AI and LNP technology offers significant advantages, including enabling the design of more personalized and precise delivery systems, streamlining the development process, and reducing the cost.
AI-guided approaches can improve the efficiency of lipid structure and formulation screening by identifying key design parameters and using predictive modeling to optimize LNP properties.
AI-guided approaches can improve the efficiency of lipid structure and formulation screening by rapidly identifying key design parameters and employing predictive modeling to optimize LNP properties.
Nanoparticle-based delivery systems can improve the stability, circulation time, and tumor-targeting precision of encapsulated CRISPR components.
The NTLA-2001 trial demonstrated the first successful use of lipid nanoparticles for in vivo CRISPR delivery in humans.
Preclinical and early-phase trials indicate that mRNA-LNPs encoding tumor-associated antigens or patient-specific neoantigens can expand cytotoxic T cells and elicit preliminary antitumor activity.
Lipid nanoparticles have enabled preferential intraocular delivery of mRNA to retinal neurons, Müller glia, and pigment epithelium while improving mRNA stability and transfection efficiency.
LNP drug product development is not straightforward because numerous factors influence product quality, including LNP composition, process parameters, and formulation composition.
LNP drug product development is not straightforward. Numerous factors influence product quality, including LNP composition, process parameters, and formulation composition.
Immunosuppressive tumor microenvironments, heterogeneous antigen expression, and suboptimal lymphoid targeting limit the efficacy of cancer vaccines delivered with LNPs.
Lipid nanoparticles protect and transport mRNA to target sites, supporting mRNA stability and efficient transfection.
LNPs effectively protect and transport mRNA to target sites, thereby ensuring its stability and efficient transfection.
Lipid nanoparticles protect nucleic acids, enhance cellular uptake, and enable efficient cytosolic delivery.
Development of mRNA-LNP delivery systems remains limited by targeting specificity, formulation complexity, and time-consuming high-throughput screening.
some challenges remain in the development of mRNA-LNP delivery systems, such as limited targeting specificity, the complexity of formulations, and the time-consuming and high-throughput screening process
Manufacturing cost and batch consistency are barriers that challenge scale-up of LNP-based cancer vaccines.
Physicochemical instability of LNP systems necessitates cold-chain logistics and complicates global deployment.
Current nanoparticle-enhanced CRISPR delivery approaches remain limited by poor delivery to solid tumors, potential off-target effects, and inconsistent nanoparticle formulations.
Manufacturing of LNP is well established and scalable equipment is available for production.
Although the manufacturing of LNP is well established and scalable equipment is available for production
Lipid nanoparticles are described as protecting mRNA from degradation and facilitating transport into the cell cytoplasm.
Engineered mRNA formats including chemically modified linear, circular, and self-amplifying RNA can achieve higher translation efficiency within a tunable expression window.
Both LNP and DC mRNA vaccine platforms can augment antitumor immunity by broadening T-cell responses and enhancing checkpoint inhibition.
Completed clinical studies indicate that personalized LNP-formulated mRNA melanoma vaccines can enhance neoantigen-specific T-cell responses.
Completed clinical studies indicate that personalized LNP-formulated mRNA melanoma vaccines can improve recurrence-free survival, particularly when combined with immune checkpoint inhibitors.
Continued refinement of delivery vehicles, neoantigen selection, and scalable manufacturing processes is needed to realize the full clinical potential of mRNA vaccines in melanoma.
DC-based mRNA vaccines show potent immunogenicity in melanoma vaccine studies.
Stronger responses with DC-based mRNA vaccines are observed when dendritic-cell maturation is optimized.
Lipid nanoparticles are currently the most relevant non-viral delivery systems for mRNA and are occasionally used for smaller nucleic acids such as siRNA.
Lipid nanoparticles (LNP) are currently the most relevant non-viral delivery systems for mRNA and occasionally for smaller nucleic acids such as small interfering RNA.
Reactogenicity and anti-PEG antibodies increase safety and dosing concerns for LNP-based cancer vaccines.
Despite encouraging preclinical outcomes of lipid nanoparticle-mRNA formulations, no candidates have progressed into retinal clinical trials.
Lipid nanoparticles offer safer and more flexible alternatives to viral vectors.
While viral vectors are effective, non-viral systems like lipid nanoparticles (LNPs) offer safer, more flexible alternatives.
The review describes dry powder formulations of mRNA-loaded lipid nanoparticles for pulmonary delivery and LNP-mediated siRNA delivery for respiratory infections as example applications.
Nanotechnology-enabled diagnostic approaches in the review include gold nanoparticles, magnetic nanoparticle biosensors, quantum dots, and AI-integrated nanosensors for rapid point-of-care or sensitive detection.
Nanotechnology-enabled prevention approaches in the review include nanofiber-enhanced masks, antiviral surface coatings, and nanoparticle-based disinfectants.
Treatment-oriented nanotechnology approaches in the review include lipid nanoparticle vaccines, virus-like particles, and targeted or controlled therapeutic delivery systems such as polymeric nanocarriers.
The review states that nanoparticle-based RNA delivery systems have led to advancements in tumor targeting, intracellular delivery, and RNA release.
Lipid nanoparticles, PLGA, chitosan, and polyethyleneimine have been widely studied as siRNA nanocarriers for rheumatoid arthritis.
Emerging carriers including metal-organic frameworks can enhance controlled release and specificity.
FDA approval of voretigene neparvovec validated the clinical viability of ocular gene therapy.
Non-viral delivery systems, particularly lipid nanoparticles and emerging platforms like microfluidics and biodegradable polymers, offer safer and more adaptable alternatives to viral vectors.
Non-viral delivery systems, particularly LNPs and emerging platforms like microfluidics and biodegradable polymers, offer safer and more adaptable alternatives to viral vectors.
Efficient and safe delivery remains a major challenge for CRISPR-based β-thalassemia therapies.
Dual AAV vectors, lipid nanoparticles, and novel biomaterials have enhanced the efficiency and specificity of gene delivery to the retina.
Non-viral systems such as lipid nanoparticles and engineered exosomes offer lower toxicity and modularity but face targeting limitations.
Lipid nanoparticles are a crucial enabler for the clinical translation of mRNA therapies because of their delivery capabilities.
Lipid nanoparticles (LNPs) have emerged as a crucial enabler for the clinical translation of mRNA therapies, thanks to their remarkable delivery capabilities.
Lipid tail modifications are discussed as nanoparticle optimization strategies for RNA cargos such as mRNA and CRISPR/Cas9.
Electroporation and microfluidic systems offered precise control over transfection parameters, improving reproducibility and scalability.
Electroporation and microfluidic systems offered precise control over transfection parameters, improving reproducibility and scalability.
Future ocular gene therapy development is expected to include prime editing, miRNA-based regulation, and combinatorial approaches with stem cell transplantation or neuroprotective agents.
Antigen discovery and delivery, including lipid nanoparticle delivery, remain challenges for mRNA vaccines against bacterial pathogens.
as well as the challenges of antigen discovery and delivery (e.g. lipid nanoparticles)
Targeting efficiency, endosomal escape, stability, immune system interactions, and scalability remain unresolved challenges for RNA nanoparticle delivery systems.
Theranostic platforms provide opportunities for real-time monitoring of biodistribution and therapeutic efficacy.
LNPs demonstrate strong efficiency in nucleic acid encapsulation and delivery and are supported by growing clinical translation.
The analysis indicates that LNPs demonstrate strong efficiency in nucleic acid encapsulation and delivery, supported by growing clinical translation.
EVs show promising biocompatibility and innate targeting to hepatic cells but face challenges in large-scale production and standardization.
EVs show promising biocompatibility and innate targeting to hepatic cells but face challenges in large-scale production and standardization.
Liposomes are versatile and well-characterized platforms capable of carrying diverse therapeutic molecules, though rapid clearance can limit their efficacy.
Liposomes remain versatile and well-characterized platforms capable of carrying diverse therapeutic molecules, though rapid clearance can limit their efficacy.
Gene augmentation, gene editing, RNA-based therapies, and optogenetics have shown significant progress in preclinical studies and clinical trials across posterior segment eye disease subtypes.
Therapeutic efficacy of mRNA requires efficient entry into target cells and expression of functional proteins.
Achieving therapeutic efficacy requires mRNA to efficiently enter target cells and express functional proteins, highlighting the urgent need for effective delivery systems.
This article reviews next-generation bacterial vaccine strategies including mRNA, DNA, self-amplifying RNA, viral vector vaccines, and nanoparticle technologies.
Here we review next-generation vaccine strategies, focusing on nucleic acid-based platforms such as mRNA, DNA, and self-amplifying RNA (saRNA), as well as viral vector vaccines. We also examine nanoparticle technologies that serve as delivery systems or adjuvant platforms across these approaches.
Nanoparticle-mediated delivery systems including RNA-coated liposomes, lipid nanoparticles, and size- and surface-modifiable nanoparticles are being advanced to address RNA delivery challenges.
mRNA vaccine design includes mRNA engineering strategies and delivery innovations such as lipid nanoparticles, polymeric nanoparticles, virus-like particles, and needle-free administration technologies.
The review covers optimization of LNP composition, innovative synthesis methods, AI-driven formula optimization, and targeted delivery strategies for mRNA-LNP cancer therapy.
It systematically summarizes strategies for optimizing LNP composition, introduces innovative synthesis methods and AI-driven formula optimization, and explores targeted delivery strategies.
Innovations in gene-delivery platforms including lentiviral vectors, AAV vectors, and lipid nanoparticles are opening avenues to modulate the hepatic tumor niche.
innovations in gene-delivery platforms, from lentiviral and AAV vectors to lipid nanoparticles, ... are opening avenues to modulate the hepatic tumor niche
Several mRNA-based therapies have been approved or are in clinical trials.
Several mRNA-based therapies have now been approved or are in clinical trials, underscoring the vast potential of mRNA technology.
Heterogeneity is presented as a central design problem for nanoparticle drug delivery in precision medicine.
The review scope explicitly includes lipid-based, polymeric, and inorganic nanoparticle systems as major precision-delivery platform classes.
Protein corona is treated as a relevant determinant of nanoparticle biological identity and delivery behavior in the review's design context.
The enhanced permeability and retention effect is presented as heterogeneous and therefore insufficient as a uniform assumption for precision nanomedicine design.
The review frames precision nanoparticle engineering as a strategy to overcome systemic, microenvironmental, and cellular barriers to drug delivery.
The supplied source summary states that lipid nanoparticles are a core delivery system for both non-replicating and self-amplifying mRNA vaccines discussed by the review.
The supplied source summary states that pseudouridine and 1-methylpseudouridine are used in mRNA vaccine platforms to suppress innate sensing and improve translation.
Approval Evidence
20 sources44 linked approval claimsfirst-pass slug lipid-nanoparticles
This review summarizes current evidence on mRNA melanoma vaccines, focusing on two leading delivery platforms: lipid nanoparticles (LNPs) and dendritic cell (DC) vaccines.
Source:
Lipid nanoparticles (LNPs) hold significant potential for mRNA-based therapeutics... LNPs effectively protect and transport mRNA to target sites, thereby ensuring its stability and efficient transfection.
Source:
Lipid nanoparticles (LNP) are currently the most relevant non-viral delivery systems for mRNA and occasionally for smaller nucleic acids such as small interfering RNA.
Source:
Advances in nanocarriers, particularly lipid nanoparticles, have enabled preferential delivery to retinal neurons, Müller glia, and pigment epithelium via intraocular administration, while improving mRNA stability and transfection efficiency.
Source:
In this context, delivery systems such as lipid nanoparticles (LNPs) play a key role, protecting mRNA from degradation and facilitating its transport into the cell cytoplasm.
Source:
By encapsulating CRISPR components within lipid, polymeric, or inorganic nanoparticles, researchers have improved their stability, circulation time, and tumor-targeting precision.
Source:
LNPs have become pivotal to this approach. Originally optimized for siRNA, LNPs' core-shell architecture protects nucleic acids, enhances cellular uptake, and enables efficient cytosolic delivery.
Source:
non-viral systems such as lipid nanoparticles and engineered exosomes offer lower toxicity and modularity but face targeting limitations
Source:
This review examines recent advancements in nanoparticle( s) (NPs) delivery systems, with a focus on ... lipid nanoparticles (LNPs)... We discussed various NP platforms and their applications, such as ... dry powder formulations of mRNA-loaded LNPs for pulmonary delivery, and LNP-mediated siRNA delivery for respiratory infections.
Source:
Innovations in viral and non-viral delivery systems, such as dual AAV vectors, lipid nanoparticles, and novel biomaterials, have enhanced the efficiency and specificity of gene delivery to the retina.
Source:
Lipid nanoparticles (LNPs) have emerged as a crucial enabler for the clinical translation of mRNA therapies, thanks to their remarkable delivery capabilities.
Source:
delivery innovations such as lipid nanoparticles (LNPs)
Source:
advantagesupports
Combining AI with LNP technology can enable more personalized and precise delivery systems, streamline development, and reduce cost.
The combination of AI and LNP technology offers significant advantages, including enabling the design of more personalized and precise delivery systems, streamlining the development process, and reducing the cost.
Source:
capability statementsupports
Nanoparticle-based delivery systems can improve the stability, circulation time, and tumor-targeting precision of encapsulated CRISPR components.
Source:
clinical milestonesupports
The NTLA-2001 trial demonstrated the first successful use of lipid nanoparticles for in vivo CRISPR delivery in humans.
Source:
clinical translationsupports
Preclinical and early-phase trials indicate that mRNA-LNPs encoding tumor-associated antigens or patient-specific neoantigens can expand cytotoxic T cells and elicit preliminary antitumor activity.
Source:
delivery claimsupports
Lipid nanoparticles have enabled preferential intraocular delivery of mRNA to retinal neurons, Müller glia, and pigment epithelium while improving mRNA stability and transfection efficiency.
Source:
development challengesupports
LNP drug product development is not straightforward because numerous factors influence product quality, including LNP composition, process parameters, and formulation composition.
LNP drug product development is not straightforward. Numerous factors influence product quality, including LNP composition, process parameters, and formulation composition.
Source:
efficacy limitationsupports
Immunosuppressive tumor microenvironments, heterogeneous antigen expression, and suboptimal lymphoid targeting limit the efficacy of cancer vaccines delivered with LNPs.
Source:
functionsupports
Lipid nanoparticles protect and transport mRNA to target sites, supporting mRNA stability and efficient transfection.
LNPs effectively protect and transport mRNA to target sites, thereby ensuring its stability and efficient transfection.
Source:
functional rolesupports
Lipid nanoparticles protect nucleic acids, enhance cellular uptake, and enable efficient cytosolic delivery.
Source:
limitationsupports
Development of mRNA-LNP delivery systems remains limited by targeting specificity, formulation complexity, and time-consuming high-throughput screening.
some challenges remain in the development of mRNA-LNP delivery systems, such as limited targeting specificity, the complexity of formulations, and the time-consuming and high-throughput screening process
Source:
limitationsupports
Manufacturing cost and batch consistency are barriers that challenge scale-up of LNP-based cancer vaccines.
Source:
limitationsupports
Physicochemical instability of LNP systems necessitates cold-chain logistics and complicates global deployment.
Source:
limitation statementsupports
Current nanoparticle-enhanced CRISPR delivery approaches remain limited by poor delivery to solid tumors, potential off-target effects, and inconsistent nanoparticle formulations.
Source:
manufacturing statussupports
Manufacturing of LNP is well established and scalable equipment is available for production.
Although the manufacturing of LNP is well established and scalable equipment is available for production
Source:
mechanistic rolesupports
Lipid nanoparticles are described as protecting mRNA from degradation and facilitating transport into the cell cytoplasm.
Source:
review summarysupports
Both LNP and DC mRNA vaccine platforms can augment antitumor immunity by broadening T-cell responses and enhancing checkpoint inhibition.
Source:
review summarysupports
Completed clinical studies indicate that personalized LNP-formulated mRNA melanoma vaccines can enhance neoantigen-specific T-cell responses.
Source:
review summarysupports
Completed clinical studies indicate that personalized LNP-formulated mRNA melanoma vaccines can improve recurrence-free survival, particularly when combined with immune checkpoint inhibitors.
Source:
review summarysupports
Continued refinement of delivery vehicles, neoantigen selection, and scalable manufacturing processes is needed to realize the full clinical potential of mRNA vaccines in melanoma.
Source:
role in fieldsupports
Lipid nanoparticles are currently the most relevant non-viral delivery systems for mRNA and are occasionally used for smaller nucleic acids such as siRNA.
Lipid nanoparticles (LNP) are currently the most relevant non-viral delivery systems for mRNA and occasionally for smaller nucleic acids such as small interfering RNA.
Source:
Comparisons
Source-stated alternatives
The abstract contrasts LNP-enabled cancer vaccination with conventional modalities such as surgery, radiotherapy, and chemotherapy, which often fail to prevent metastasis or recurrence. It also discusses design alternatives within LNP systems, including PEG alternatives, biodegradable lipids, ligand-mediated targeting, and different delivery routes.; The paper also mentions polymeric and inorganic nanoparticles as alternative nanoparticle classes.; The review notes biodegradable polymer-based delivery systems as an alternative class under development.; The abstract contrasts mRNA delivery systems broadly with adeno-associated virus DNA overexpression platforms and highlights lipid nanoparticles as a particularly important non-viral carrier class.; The abstract contrasts LNPs with viral delivery only indirectly by calling them non-viral delivery systems. No specific alternative non-viral platform is named in the provided source text.; No direct alternative delivery platform is named in the abstract. The source instead contrasts conventional development with AI-guided optimization of LNPs.; The main alternative platform named in the review is dendritic-cell vaccination. The review contrasts LNP delivery with DC-based mRNA vaccine approaches rather than claiming one universally replaces the other.; The abstract contrasts LNPs with viral vectors and also discusses biodegradable polymers, electroporation, peptide-based carriers, and microfluidic platforms as other non-viral approaches.; The abstract contrasts lipid nanoparticles with lentiviral vectors and AAV vectors as other gene-delivery platforms.; The review compares LNPs against extracellular vesicles and liposomes for hepatic delivery.; The review compares multiple vaccine platforms including DNA, self-amplifying RNA, and viral vector vaccines, and also discusses nanoparticle technologies more broadly.; The review also names virus-like particles, targeted drug delivery systems, and polymeric nanocarriers as nearby treatment-oriented nanotechnology approaches.; The abstract contrasts lipid nanoparticles with PLGA, chitosan, polyethyleneimine, dendrimers, self-assembling peptides, mesoporous silica, and MOFs.; The abstract contrasts LNPs with polymeric nanoparticles, virus-like particles, and needle-free administration technologies.; The abstract emphasizes LNPs as a crucial enabler but does not name alternative non-LNP delivery systems.; The review contrasts lipid nanoparticles with dual AAV vectors and novel biomaterials as other retinal delivery options.; The abstract contrasts lipid nanoparticles with viral vectors and engineered exosomes.; The review places LNPs alongside RNA-coated liposomes and size- and surface-modifiable nanoparticles as alternative nanoparticle delivery platforms.; The same review scope also includes polymeric and inorganic nanoparticle systems as alternative material platforms.; The supplied summary names cationic nanoemulsion, protamine complexation, electroporation, and PEI-based delivery as nearby alternatives discussed around the review.
Source:
The abstract contrasts LNP-enabled cancer vaccination with conventional modalities such as surgery, radiotherapy, and chemotherapy, which often fail to prevent metastasis or recurrence. It also discusses design alternatives within LNP systems, including PEG alternatives, biodegradable lipids, ligand-mediated targeting, and different delivery routes.
Source:
The paper also mentions polymeric and inorganic nanoparticles as alternative nanoparticle classes.
Source:
The review notes biodegradable polymer-based delivery systems as an alternative class under development.
Source:
The abstract contrasts mRNA delivery systems broadly with adeno-associated virus DNA overexpression platforms and highlights lipid nanoparticles as a particularly important non-viral carrier class.
Source:
The abstract contrasts LNPs with viral delivery only indirectly by calling them non-viral delivery systems. No specific alternative non-viral platform is named in the provided source text.
Source:
No direct alternative delivery platform is named in the abstract. The source instead contrasts conventional development with AI-guided optimization of LNPs.
Source:
The main alternative platform named in the review is dendritic-cell vaccination. The review contrasts LNP delivery with DC-based mRNA vaccine approaches rather than claiming one universally replaces the other.
Source:
The abstract contrasts LNPs with viral vectors and also discusses biodegradable polymers, electroporation, peptide-based carriers, and microfluidic platforms as other non-viral approaches.
Source:
The abstract contrasts lipid nanoparticles with lentiviral vectors and AAV vectors as other gene-delivery platforms.
Source:
The review compares LNPs against extracellular vesicles and liposomes for hepatic delivery.
Source:
The review compares multiple vaccine platforms including DNA, self-amplifying RNA, and viral vector vaccines, and also discusses nanoparticle technologies more broadly.
Source:
The review also names virus-like particles, targeted drug delivery systems, and polymeric nanocarriers as nearby treatment-oriented nanotechnology approaches.
Source:
The abstract contrasts lipid nanoparticles with PLGA, chitosan, polyethyleneimine, dendrimers, self-assembling peptides, mesoporous silica, and MOFs.
Source:
The abstract contrasts LNPs with polymeric nanoparticles, virus-like particles, and needle-free administration technologies.
Source:
The abstract emphasizes LNPs as a crucial enabler but does not name alternative non-LNP delivery systems.
Source:
The review contrasts lipid nanoparticles with dual AAV vectors and novel biomaterials as other retinal delivery options.
Source:
The abstract contrasts lipid nanoparticles with viral vectors and engineered exosomes.
Source:
The review places LNPs alongside RNA-coated liposomes and size- and surface-modifiable nanoparticles as alternative nanoparticle delivery platforms.
Source:
The same review scope also includes polymeric and inorganic nanoparticle systems as alternative material platforms.
Source:
The supplied summary names cationic nanoemulsion, protamine complexation, electroporation, and PEI-based delivery as nearby alternatives discussed around the review.
Source-backed strengths
core-shell architecture protects nucleic acids; enhances cellular uptake; clinically validated in infectious-disease mRNA vaccines; clinically referenced in the NTLA-2001 example for in vivo CRISPR delivery in humans; protect mRNA from degradation; facilitate transport into the cell cytoplasm; described as playing a key role in therapeutic mRNA vaccine delivery; preferential delivery to multiple retinal cell populations; improved mRNA stability; improved transfection efficiency; encouraging preclinical outcomes; described as currently the most relevant non-viral delivery system for mRNA; manufacturing is well established; scalable equipment is available for production; protect mRNA cargo; transport mRNA to target sites; already used successfully in SARS-CoV-2 mRNA vaccines; associated with enhanced neoantigen-specific T-cell responses in completed clinical studies; associated with improved recurrence-free survival particularly when combined with immune checkpoint inhibitors; described as safer and more adaptable than viral vectors; highlighted as particularly important among non-viral delivery systems; presented as part of the set of innovations opening avenues to modulate the hepatic tumor niche; strong efficiency in nucleic acid encapsulation and delivery; supported by growing clinical translation; explicitly highlighted as a delivery component across next-generation bacterial vaccine approaches; highlighted as a significant nanotechnology contribution to COVID-19 treatment efforts; presented as an advanced formulation for controlled delivery; widely studied; presented as a key delivery innovation in mRNA vaccine development; remarkable delivery capabilities; crucial enabler for clinical translation; review states they have enhanced retinal gene delivery efficiency and specificity; non-viral positioning suggests an alternative to viral vectors; lower toxicity; modularity; associated with tumor targeting; associated with intracellular delivery; associated with RNA release; supports multiple RNA cargo types including mRNA and siRNA; explicitly included as a major nanoparticle class within the review's scope; described as a core delivery system in the review scope
Source:
core-shell architecture protects nucleic acids
Source:
enhances cellular uptake
Source:
clinically validated in infectious-disease mRNA vaccines
Source:
clinically referenced in the NTLA-2001 example for in vivo CRISPR delivery in humans
Source:
protect mRNA from degradation
Source:
facilitate transport into the cell cytoplasm
Source:
described as playing a key role in therapeutic mRNA vaccine delivery
Source:
preferential delivery to multiple retinal cell populations
Source:
improved mRNA stability
Source:
improved transfection efficiency
Source:
encouraging preclinical outcomes
Source:
described as currently the most relevant non-viral delivery system for mRNA
Source:
manufacturing is well established
Source:
scalable equipment is available for production
Source:
protect mRNA cargo
Source:
transport mRNA to target sites
Source:
already used successfully in SARS-CoV-2 mRNA vaccines
Source:
associated with enhanced neoantigen-specific T-cell responses in completed clinical studies
Source:
associated with improved recurrence-free survival particularly when combined with immune checkpoint inhibitors
Source:
described as safer and more adaptable than viral vectors
Source:
highlighted as particularly important among non-viral delivery systems
Source:
presented as part of the set of innovations opening avenues to modulate the hepatic tumor niche
Source:
strong efficiency in nucleic acid encapsulation and delivery
Source:
supported by growing clinical translation
Source:
explicitly highlighted as a delivery component across next-generation bacterial vaccine approaches
Source:
highlighted as a significant nanotechnology contribution to COVID-19 treatment efforts
Source:
presented as an advanced formulation for controlled delivery
Source:
widely studied
Source:
presented as a key delivery innovation in mRNA vaccine development
Source:
remarkable delivery capabilities
Source:
crucial enabler for clinical translation
Source:
review states they have enhanced retinal gene delivery efficiency and specificity
Source:
non-viral positioning suggests an alternative to viral vectors
Source:
lower toxicity
Source:
modularity
Source:
associated with tumor targeting
Source:
associated with intracellular delivery
Source:
associated with RNA release
Source:
supports multiple RNA cargo types including mRNA and siRNA
Source:
explicitly included as a major nanoparticle class within the review's scope
Source:
described as a core delivery system in the review scope
Compared with Adeno-associated virus
The abstract contrasts mRNA delivery systems broadly with adeno-associated virus DNA overexpression platforms and highlights lipid nanoparticles as a particularly important non-viral carrier class.; The abstract contrasts LNPs with viral vectors and also discusses biodegradable polymers, electroporation, peptide-based carriers, and microfluidic platforms as other non-viral approaches.; The abstract contrasts lipid nanoparticles with lentiviral vectors and AAV vectors as other gene-delivery platforms.; The review contrasts lipid nanoparticles with dual AAV vectors and novel biomaterials as other retinal delivery options.; The abstract contrasts lipid nanoparticles with viral vectors and engineered exosomes.
Shared frame: source-stated alternative in extracted literature
Strengths here: core-shell architecture protects nucleic acids; enhances cellular uptake; clinically validated in infectious-disease mRNA vaccines.
Relative tradeoffs: manufacturing cost and batch consistency challenge scale-up; physicochemical instability necessitates cold-chain logistics; reactogenicity and anti-PEG antibodies increase safety and dosing concerns.
Source:
The abstract contrasts mRNA delivery systems broadly with adeno-associated virus DNA overexpression platforms and highlights lipid nanoparticles as a particularly important non-viral carrier class.
Source:
The abstract contrasts LNPs with viral vectors and also discusses biodegradable polymers, electroporation, peptide-based carriers, and microfluidic platforms as other non-viral approaches.
Source:
The abstract contrasts lipid nanoparticles with lentiviral vectors and AAV vectors as other gene-delivery platforms.
Source:
The review contrasts lipid nanoparticles with dual AAV vectors and novel biomaterials as other retinal delivery options.
Source:
The abstract contrasts lipid nanoparticles with viral vectors and engineered exosomes.
Compared with dendrimers
The abstract contrasts lipid nanoparticles with PLGA, chitosan, polyethyleneimine, dendrimers, self-assembling peptides, mesoporous silica, and MOFs.
Shared frame: source-stated alternative in extracted literature
Strengths here: core-shell architecture protects nucleic acids; enhances cellular uptake; clinically validated in infectious-disease mRNA vaccines.
Relative tradeoffs: manufacturing cost and batch consistency challenge scale-up; physicochemical instability necessitates cold-chain logistics; reactogenicity and anti-PEG antibodies increase safety and dosing concerns.
Source:
The abstract contrasts lipid nanoparticles with PLGA, chitosan, polyethyleneimine, dendrimers, self-assembling peptides, mesoporous silica, and MOFs.
Compared with engineered exosomes
The abstract contrasts lipid nanoparticles with viral vectors and engineered exosomes.
Shared frame: source-stated alternative in extracted literature
Strengths here: core-shell architecture protects nucleic acids; enhances cellular uptake; clinically validated in infectious-disease mRNA vaccines.
Relative tradeoffs: manufacturing cost and batch consistency challenge scale-up; physicochemical instability necessitates cold-chain logistics; reactogenicity and anti-PEG antibodies increase safety and dosing concerns.
Source:
The abstract contrasts lipid nanoparticles with viral vectors and engineered exosomes.
Compared with Exosomes
The review compares LNPs against extracellular vesicles and liposomes for hepatic delivery.; The abstract contrasts lipid nanoparticles with viral vectors and engineered exosomes.
Shared frame: source-stated alternative in extracted literature
Strengths here: core-shell architecture protects nucleic acids; enhances cellular uptake; clinically validated in infectious-disease mRNA vaccines.
Relative tradeoffs: manufacturing cost and batch consistency challenge scale-up; physicochemical instability necessitates cold-chain logistics; reactogenicity and anti-PEG antibodies increase safety and dosing concerns.
Source:
The review compares LNPs against extracellular vesicles and liposomes for hepatic delivery.
Source:
The abstract contrasts lipid nanoparticles with viral vectors and engineered exosomes.
Compared with extracellular vesicles
The review compares LNPs against extracellular vesicles and liposomes for hepatic delivery.
Shared frame: source-stated alternative in extracted literature
Strengths here: core-shell architecture protects nucleic acids; enhances cellular uptake; clinically validated in infectious-disease mRNA vaccines.
Relative tradeoffs: manufacturing cost and batch consistency challenge scale-up; physicochemical instability necessitates cold-chain logistics; reactogenicity and anti-PEG antibodies increase safety and dosing concerns.
Source:
The review compares LNPs against extracellular vesicles and liposomes for hepatic delivery.
Compared with lipid nanoparticle
The abstract contrasts mRNA delivery systems broadly with adeno-associated virus DNA overexpression platforms and highlights lipid nanoparticles as a particularly important non-viral carrier class.; The abstract contrasts lipid nanoparticles with lentiviral vectors and AAV vectors as other gene-delivery platforms.; The abstract contrasts lipid nanoparticles with PLGA, chitosan, polyethyleneimine, dendrimers, self-assembling peptides, mesoporous silica, and MOFs.; The review contrasts lipid nanoparticles with dual AAV vectors and novel biomaterials as other retinal delivery options.; The abstract contrasts lipid nanoparticles with viral vectors and engineered exosomes.
Shared frame: source-stated alternative in extracted literature
Strengths here: core-shell architecture protects nucleic acids; enhances cellular uptake; clinically validated in infectious-disease mRNA vaccines.
Relative tradeoffs: manufacturing cost and batch consistency challenge scale-up; physicochemical instability necessitates cold-chain logistics; reactogenicity and anti-PEG antibodies increase safety and dosing concerns.
Source:
The abstract contrasts mRNA delivery systems broadly with adeno-associated virus DNA overexpression platforms and highlights lipid nanoparticles as a particularly important non-viral carrier class.
Source:
The abstract contrasts lipid nanoparticles with lentiviral vectors and AAV vectors as other gene-delivery platforms.
Source:
The abstract contrasts lipid nanoparticles with PLGA, chitosan, polyethyleneimine, dendrimers, self-assembling peptides, mesoporous silica, and MOFs.
Source:
The review contrasts lipid nanoparticles with dual AAV vectors and novel biomaterials as other retinal delivery options.
Source:
The abstract contrasts lipid nanoparticles with viral vectors and engineered exosomes.
Compared with LNP
The abstract contrasts mRNA delivery systems broadly with adeno-associated virus DNA overexpression platforms and highlights lipid nanoparticles as a particularly important non-viral carrier class.; The abstract contrasts lipid nanoparticles with lentiviral vectors and AAV vectors as other gene-delivery platforms.; The abstract contrasts lipid nanoparticles with PLGA, chitosan, polyethyleneimine, dendrimers, self-assembling peptides, mesoporous silica, and MOFs.; The review contrasts lipid nanoparticles with dual AAV vectors and novel biomaterials as other retinal delivery options.; The abstract contrasts lipid nanoparticles with viral vectors and engineered exosomes.
Shared frame: source-stated alternative in extracted literature
Strengths here: core-shell architecture protects nucleic acids; enhances cellular uptake; clinically validated in infectious-disease mRNA vaccines.
Relative tradeoffs: manufacturing cost and batch consistency challenge scale-up; physicochemical instability necessitates cold-chain logistics; reactogenicity and anti-PEG antibodies increase safety and dosing concerns.
Source:
The abstract contrasts mRNA delivery systems broadly with adeno-associated virus DNA overexpression platforms and highlights lipid nanoparticles as a particularly important non-viral carrier class.
Source:
The abstract contrasts lipid nanoparticles with lentiviral vectors and AAV vectors as other gene-delivery platforms.
Source:
The abstract contrasts lipid nanoparticles with PLGA, chitosan, polyethyleneimine, dendrimers, self-assembling peptides, mesoporous silica, and MOFs.
Source:
The review contrasts lipid nanoparticles with dual AAV vectors and novel biomaterials as other retinal delivery options.
Source:
The abstract contrasts lipid nanoparticles with viral vectors and engineered exosomes.
Compared with mRNA-lipid nanoparticles
The abstract contrasts LNPs with viral delivery only indirectly by calling them non-viral delivery systems. No specific alternative non-viral platform is named in the provided source text.; No direct alternative delivery platform is named in the abstract. The source instead contrasts conventional development with AI-guided optimization of LNPs.; The abstract contrasts LNPs with viral vectors and also discusses biodegradable polymers, electroporation, peptide-based carriers, and microfluidic platforms as other non-viral approaches.; The review compares LNPs against extracellular vesicles and liposomes for hepatic delivery.; The abstract contrasts LNPs with polymeric nanoparticles, virus-like particles, and needle-free administration technologies.; The abstract emphasizes LNPs as a crucial enabler but does not name alternative non-LNP delivery systems.; The review places LNPs alongside RNA-coated liposomes and size- and surface-modifiable nanoparticles as alternative nanoparticle delivery platforms.
Shared frame: source-stated alternative in extracted literature
Strengths here: core-shell architecture protects nucleic acids; enhances cellular uptake; clinically validated in infectious-disease mRNA vaccines.
Relative tradeoffs: manufacturing cost and batch consistency challenge scale-up; physicochemical instability necessitates cold-chain logistics; reactogenicity and anti-PEG antibodies increase safety and dosing concerns.
Source:
The abstract contrasts LNPs with viral delivery only indirectly by calling them non-viral delivery systems. No specific alternative non-viral platform is named in the provided source text.
Source:
No direct alternative delivery platform is named in the abstract. The source instead contrasts conventional development with AI-guided optimization of LNPs.
Source:
The abstract contrasts LNPs with viral vectors and also discusses biodegradable polymers, electroporation, peptide-based carriers, and microfluidic platforms as other non-viral approaches.
Source:
The review compares LNPs against extracellular vesicles and liposomes for hepatic delivery.
Source:
The abstract contrasts LNPs with polymeric nanoparticles, virus-like particles, and needle-free administration technologies.
Source:
The abstract emphasizes LNPs as a crucial enabler but does not name alternative non-LNP delivery systems.
Source:
The review places LNPs alongside RNA-coated liposomes and size- and surface-modifiable nanoparticles as alternative nanoparticle delivery platforms.
Compared with mRNA-loaded lipid nanoparticles
The abstract contrasts LNPs with viral delivery only indirectly by calling them non-viral delivery systems. No specific alternative non-viral platform is named in the provided source text.; No direct alternative delivery platform is named in the abstract. The source instead contrasts conventional development with AI-guided optimization of LNPs.; The abstract contrasts LNPs with viral vectors and also discusses biodegradable polymers, electroporation, peptide-based carriers, and microfluidic platforms as other non-viral approaches.; The review compares LNPs against extracellular vesicles and liposomes for hepatic delivery.; The abstract contrasts LNPs with polymeric nanoparticles, virus-like particles, and needle-free administration technologies.; The abstract emphasizes LNPs as a crucial enabler but does not name alternative non-LNP delivery systems.; The review places LNPs alongside RNA-coated liposomes and size- and surface-modifiable nanoparticles as alternative nanoparticle delivery platforms.
Shared frame: source-stated alternative in extracted literature
Strengths here: core-shell architecture protects nucleic acids; enhances cellular uptake; clinically validated in infectious-disease mRNA vaccines.
Relative tradeoffs: manufacturing cost and batch consistency challenge scale-up; physicochemical instability necessitates cold-chain logistics; reactogenicity and anti-PEG antibodies increase safety and dosing concerns.
Source:
The abstract contrasts LNPs with viral delivery only indirectly by calling them non-viral delivery systems. No specific alternative non-viral platform is named in the provided source text.
Source:
No direct alternative delivery platform is named in the abstract. The source instead contrasts conventional development with AI-guided optimization of LNPs.
Source:
The abstract contrasts LNPs with viral vectors and also discusses biodegradable polymers, electroporation, peptide-based carriers, and microfluidic platforms as other non-viral approaches.
Source:
The review compares LNPs against extracellular vesicles and liposomes for hepatic delivery.
Source:
The abstract contrasts LNPs with polymeric nanoparticles, virus-like particles, and needle-free administration technologies.
Source:
The abstract emphasizes LNPs as a crucial enabler but does not name alternative non-LNP delivery systems.
Source:
The review places LNPs alongside RNA-coated liposomes and size- and surface-modifiable nanoparticles as alternative nanoparticle delivery platforms.
Compared with polymeric vesicles
The review compares LNPs against extracellular vesicles and liposomes for hepatic delivery.
Shared frame: source-stated alternative in extracted literature
Strengths here: core-shell architecture protects nucleic acids; enhances cellular uptake; clinically validated in infectious-disease mRNA vaccines.
Relative tradeoffs: manufacturing cost and batch consistency challenge scale-up; physicochemical instability necessitates cold-chain logistics; reactogenicity and anti-PEG antibodies increase safety and dosing concerns.
Source:
The review compares LNPs against extracellular vesicles and liposomes for hepatic delivery.
Compared with self-amplifying RNA vaccines
The review compares multiple vaccine platforms including DNA, self-amplifying RNA, and viral vector vaccines, and also discusses nanoparticle technologies more broadly.
Shared frame: source-stated alternative in extracted literature
Strengths here: core-shell architecture protects nucleic acids; enhances cellular uptake; clinically validated in infectious-disease mRNA vaccines.
Relative tradeoffs: manufacturing cost and batch consistency challenge scale-up; physicochemical instability necessitates cold-chain logistics; reactogenicity and anti-PEG antibodies increase safety and dosing concerns.
Source:
The review compares multiple vaccine platforms including DNA, self-amplifying RNA, and viral vector vaccines, and also discusses nanoparticle technologies more broadly.
Compared with virus-like particles
The review also names virus-like particles, targeted drug delivery systems, and polymeric nanocarriers as nearby treatment-oriented nanotechnology approaches.; The abstract contrasts LNPs with polymeric nanoparticles, virus-like particles, and needle-free administration technologies.
Shared frame: source-stated alternative in extracted literature
Strengths here: core-shell architecture protects nucleic acids; enhances cellular uptake; clinically validated in infectious-disease mRNA vaccines.
Relative tradeoffs: manufacturing cost and batch consistency challenge scale-up; physicochemical instability necessitates cold-chain logistics; reactogenicity and anti-PEG antibodies increase safety and dosing concerns.
Source:
The review also names virus-like particles, targeted drug delivery systems, and polymeric nanocarriers as nearby treatment-oriented nanotechnology approaches.
Source:
The abstract contrasts LNPs with polymeric nanoparticles, virus-like particles, and needle-free administration technologies.
Compared with virus-like particle vaccine platform
The review also names virus-like particles, targeted drug delivery systems, and polymeric nanocarriers as nearby treatment-oriented nanotechnology approaches.; The abstract contrasts LNPs with polymeric nanoparticles, virus-like particles, and needle-free administration technologies.
Shared frame: source-stated alternative in extracted literature
Strengths here: core-shell architecture protects nucleic acids; enhances cellular uptake; clinically validated in infectious-disease mRNA vaccines.
Relative tradeoffs: manufacturing cost and batch consistency challenge scale-up; physicochemical instability necessitates cold-chain logistics; reactogenicity and anti-PEG antibodies increase safety and dosing concerns.
Source:
The review also names virus-like particles, targeted drug delivery systems, and polymeric nanocarriers as nearby treatment-oriented nanotechnology approaches.
Source:
The abstract contrasts LNPs with polymeric nanoparticles, virus-like particles, and needle-free administration technologies.
Ranked Citations
- 1.
- 2.
- 3.
- 4.
- 5.
- 6.
- 7.
- 8.
- 9.
- 10.
- 11.
- 12.
- 13.
- 14.
- 15.
- 16.
- 17.
- 18.
- 19.
- 20.